Compare ProShares Bitcoin ETF (BITO) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Bitcoin ETF vs Danaher Corporation — how do they compare? ProShares Bitcoin ETF trades at $8.76, while Danaher Corporation trades at $199.47 (market cap $140.88B). The key difference: Danaher Corporation pays a 0.8% dividend while ProShares Bitcoin ETF pays none, and Danaher Corporation is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITO | DHR | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $22.93 | $242.05 |
52-Week Low | $7.98 | $161.91 |
Market Cap | — | $140.88B |
Enterprise Value | — | $153.66B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.44, down 2.65% today amid bearish technical signals with 12 sell indicators versus 4 buy signals. The ETF faces challenges with declining distributions and negative sentiment as crypto markets struggle. Recent dividend payments of $0.01-$0.02 per share provide limited offset to the fund's 24.26% five-year decline.
The outlook remains cautious with structural costs and Bitcoin correlation concerns weighing on performance. Key risks include management fee drag, distribution volatility, and crypto market exposure. Investors should monitor fee structure efficiency and Bitcoin market stability for potential recovery catalysts.
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Bitcoin ETF
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
